CALB2

Across TCGA pan-cancer cohorts, CALB2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CALB2 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CALB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CALB2 expression acts as an unfavorable survival marker.

BRCA, LUSC, and HNSC are the cancer types where CALB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.287	0.924	<.001	36	view →
LUSC	OS	Median	All	0.222	0.663	<.001	20	view →
HNSC	OS	Median	All	0.138	0.715	<.001	18	view →
ACC	DFS	Median	All	0.068	0.667	.005	12	view →
LUAD	OS	Median	II,III,IV	0.090	0.677	<.001	8	view →
COAD	OS	Median	II,III,IV	0.454	0.791	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CALB2–BRCA (OS)

Open the BRCA breakdown →